Reciprocal relationship from LITS graph: compensation decision process, but it does not attempt to set executive compensation to a specific benchmark level, or percentile as compared to executive com…
All product sales of Jelmyto and Zusduri are recognized through the Company's arrangements with two customers as defined by ASC 606, both of which are third-party national specialty distributors.
All product sales of Jelmyto and Zusduri are recognized through the Company's arrangements with two customers as defined by ASC 606, both of which are third-party national specialty distributors.
political, economic and military conditions in Israel.* Our research and development facility is located in Ra’anana, Israel, and certain of our key vendors and suppliers, including Isotopia Molecula…
UroGen Pharma Ltd. Debt Obligations
Instrument
Description
Confidence
Evidence
URGN-DEBT
Debt stack $197.1M
90%
Market cache reports total debt of $197.1M.
URGN-DEBT-13241
Warrants outstanding: 18641000
90%
xbrl warrant detail from xbrl 2024-12-31.
URGN-DEBT-13242
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2025-12-31.
UroGen Pharma Ltd. Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for UroGen Pharma Ltd..
UroGen Pharma Ltd. Ownership
Holder
Name
Confidence
Evidence
URGN-OWNER-MORGAN-STANLEY
MORGAN STANLEY
90%
13F overlay lists MORGAN STANLEY as top holder; 174 tracked holders.
